Detalhe da pesquisa
1.
Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
Clin Infect Dis
; 76(4): 573-581, 2023 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200701
2.
Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients.
Antimicrob Agents Chemother
; 66(8): e0076622, 2022 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35862749
3.
Polyuria and cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
BMC Neurol
; 15: 201, 2015 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26462796
4.
Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients.
Front Immunol
; 15: 1352330, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38694513
5.
Long-term Outcomes of Patients With HIV and Pneumocystis jirovecii Pneumonia in the Antiretroviral Therapy Era.
Open Forum Infect Dis
; 10(8): ofad408, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37577116
6.
COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir.
medRxiv
; 2022 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35734093